SCHEMBL24253455

SCHEMBL24253455

Oc1cn2ccnc2nc1S

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.36
ALDH1A1 P00352 12/20 0.35
KDM4E B2RXH2 11/20 0.35
HPGD P15428 7/20 0.35
GLA P06280 4/20 0.35
HSD17B10 Q99714 3/20 0.35
GAA P10253 6/20 0.33
MAPT P10636 4/20 0.33
POLB P06746 3/20 0.33
GFER P55789 1/20 0.33
RAB9A P51151 8/20 0.33
NPC1 O15118 5/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
TP53 P04637 1/20 0.33
RXFP1 Q9HBX9 1/20 0.31
LMNA P02545 1/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23465518 0.77 DYRK1A (0.36) DYRK1AALDH1A1KDM4EHPGDGLA
SCHEMBL25092575 0.77 ALDH1A1 (0.39) DYRK1AALDH1A1KDM4EHPGDGLA
SCHEMBL25092440 0.77 DYRK1A (0.33) DYRK1AALDH1A1KDM4EHPGDGLA
SCHEMBL24874238 0.74 KDM4E (0.32) DYRK1AALDH1A1KDM4EHPGDGLA
SCHEMBL24253538 0.73 KDM4E (0.33) DYRK1AALDH1A1KDM4EHPGDGLA
SCHEMBL15688379 0.69 ALDH1A1 (0.39) DYRK1AALDH1A1KDM4EHPGDGLA
SCHEMBL25064768 0.67 KDM4E (0.32) DYRK1AALDH1A1KDM4EHPGDGLA
SCHEMBL24253459 0.66 KDM4E (0.33) DYRK1AALDH1A1KDM4EHPGDGLA
SCHEMBL22448220 0.64 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDGLAHSD17B10
SCHEMBL259600 0.64 ALDH1A1 (0.41) DYRK1AALDH1A1KDM4EHPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 DYRK1A 4465/4885ALDH1A1 3964/4885KDM4E 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.